[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 41 of about 41
1. Leblanc J, Kongkam P: Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) Diagnosis of Recurrent Anal Cancer After Chemoradiation and Negative Forceps Biopsies: A Case Report. Clin Med Oncol; 2009;3:59-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) Diagnosis of Recurrent Anal Cancer After Chemoradiation and Negative Forceps Biopsies: A Case Report.
  • A 69-year-old woman with a history of uT2 N0 post-treated anal squamous cell cancer (SCC) presented for EUS for perianal pain.
  • A sigmoidoscopy revealed mild narrowing of the anal canal and an ulcerated friable mucosa in the same area.
  • While endoscopic biopsy of suspected anal recurrences is usually sufficient, histologic or cytologic confirmation are necessary, as radiation-induced changes are difficult to differentiate from tumor recurrence.
  • This case demonstrates that EUS-FNA is useful in surveillance of anal SCC when there is a high clinical suspicion of recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1996 Jul;91(7):1309-11 [8677984.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):906-12 [10201455.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):16-22 [11786758.001]
  • [Cites] Br J Surg. 2003 Mar;90(3):346-50 [12594671.001]
  • [Cites] Lancet Oncol. 2004 Mar;5(3):149-57 [15003197.001]
  • [Cites] Cancer. 2004 Sep 1;101(5):940-7 [15329901.001]
  • [Cites] Cancer Invest. 2006 Aug-Sep;24(5):535-44 [16939964.001]
  • (PMID = 20689610.001).
  • [ISSN] 1177-9314
  • [Journal-full-title] Clinical medicine. Oncology
  • [ISO-abbreviation] Clin Med Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2872600
  •  go-up   go-down


2. Kumar GK, Chandra SS, Krishnan R: Local excision inadequate in the treatment of anal canal leiomyosarcoma. Saudi J Gastroenterol; 2010 Jul-Sep;16(3):226-7
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local excision inadequate in the treatment of anal canal leiomyosarcoma.
  • Leiomyosarcoma of the anal canal is an uncommon neoplasm of the gastrointestinal tract.
  • We report a 45-year-old lady with anal canal leiomyosarcoma.
  • In the setting of a recurrent tumor with high-grade histological appearance, local excision would be deemed unsafe.
  • [MeSH-major] Anal Canal / surgery. Anus Neoplasms / surgery. Leiomyosarcoma / surgery

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aust N Z J Surg. 1993 Sep;63(9):703-9 [8363480.001]
  • [Cites] J Chir (Paris). 1988 Apr;125(4):245-8 [3392131.001]
  • [Cites] Postgrad Med J. 1996 May;72(847):304-6 [8761508.001]
  • [Cites] J Med Assoc Ga. 1991 Dec;80(12):685-99 [1800593.001]
  • [Cites] Cancer. 1991 Oct 1;68(7):1640-3 [1893364.001]
  • (PMID = 20616423.001).
  • [ISSN] 1998-4049
  • [Journal-full-title] Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
  • [ISO-abbreviation] Saudi J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  • [Other-IDs] NLM/ PMC3003215
  •  go-up   go-down


3. Sana S, Khan AU: Clinical trials in the management of anal cancer. Clin Colon Rectal Surg; 2009 May;22(2):115-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical trials in the management of anal cancer.
  • Our understandings of anal canal cancer pathogenesis and treatment have undergone significant changes due to continuing research into its pathogenesis and the results of major clinical trials conducted over the past 20 years.
  • Anal canal cancer can be cured by combined modality chemoradiation therapy, a treatment that preserves continence and reserves abdominoperineal resection of the rectum and anal canal in patients with recurrent or residual disease after primary chemoradiotherapy.
  • This article aims to provide a summary of recently completed and ongoing clinical trials in the management of anal canal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2550-7 [18427149.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):119-26 [18472366.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] AIDS. 1994 Mar;8(3):283-95 [8031509.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3121-5 [8955657.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Am J Surg. 1985 Jan;149(1):95-101 [3966647.001]
  • (PMID = 20436836.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780239
  • [Keywords] NOTNLM ; Anal canal cancer / chemotherapy / radiation therapy
  •  go-up   go-down


Advertisement
4. Christensen AF, Nyhuus B, Nielsen MB: Interobserver and intraobserver variation of two-dimensional and three-dimensional anal endosonography in the evaluation of recurrent anal cancer. Dis Colon Rectum; 2009 Mar;52(3):484-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interobserver and intraobserver variation of two-dimensional and three-dimensional anal endosonography in the evaluation of recurrent anal cancer.
  • PURPOSE: This study was designed to evaluate the interobserver and intraobserver agreement of two-dimensional (2-D) and three-dimensional (3-D) anal endosonography for the detection of local recurrence anal carcinoma.
  • METHODS: Thirty-six patients were treated for anal carcinoma, and seven had recurrent disease.
  • CONCLUSIONS: Three-dimensional endosonography proved to have significantly better interobserver and intraobserver agreement than 2-D endosonography concerning detection of recurrent anal cancer.
  • [MeSH-major] Anus Neoplasms / ultrasonography. Endosonography. Neoplasm Recurrence, Local / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / ultrasonography. Female. Humans. Imaging, Three-Dimensional. Male. Middle Aged. Observer Variation. Retrospective Studies

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19333050.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Nahas SC, Nahas CS, Silva Filho EV, Levi JE, Atui FC, Marques CF: Perianal squamous cell carcinoma with high-grade anal intraepithelial neoplasia in an HIV-positive patient using highly active antiretroviral therapy: case report. Sao Paulo Med J; 2007 Sep 6;125(5):292-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perianal squamous cell carcinoma with high-grade anal intraepithelial neoplasia in an HIV-positive patient using highly active antiretroviral therapy: case report.
  • CONTEXT: Highly active antiretroviral therapy (HAART) has turned human immunodeficiency virus (HIV) infection into a chronic condition, and this has led to increased incidence of anal dysplasia among HIV-positive patients.
  • Routine anal evaluation including the anal canal and perianal area is recommended for this population, especially for patients infected by oncogenic human papillomavirus (HPV) types.
  • CASE REPORT: A 54-year-old homosexual HIV-positive man presented with a six-year history of recurrent perianal and anal warts.
  • He presented some condylomatous spreading lesions occupying part of the anal canal and the perianal skin, and also a well-demarcated slightly painful perianal plaque of dimensions 1.0 x 1.0 cm.
  • Both anal canal Pap smears and biopsies guided by high-resolution anoscopy revealed high-grade squamous intraepithelial lesion.
  • HPV DNA testing of the anus detected the presence of HPV-16 type.
  • Histological analysis on the excised tissue revealed high-grade squamous intraepithelial lesion with one focus of microinvasive squamous cell cancer measuring 1 mm.
  • The patient showed pathological evidence of recurrent anal and perianal high-grade squamous intraepithelial lesions at the sixth-month follow-up and required further ablation of those lesions.
  • However no invasive squamous cell carcinoma recurrence has been detected so far.
  • [MeSH-major] Antiretroviral Therapy, Highly Active / adverse effects. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. HIV Seropositivity / drug therapy. Human papillomavirus 16 / isolation & purification. Papillomavirus Infections / pathology
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / virology. DNA, Viral / analysis. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnosis


6. Rouquie D, Lasser P, Castaing M, Boige V, Goéré D, Pignon JP, Ducreux M, Elias D, Pocard M: [Complete (R0) resection is the only valid prognostic factor in abdominoperineal resection for recurrent cancer of the anal canal (a consecutive series of 95 patients)]. J Chir (Paris); 2008 Jul-Aug;145(4):335-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete (R0) resection is the only valid prognostic factor in abdominoperineal resection for recurrent cancer of the anal canal (a consecutive series of 95 patients)].
  • [Transliterated title] Résection R0, seul facteur pronostique dans les amputations abdominopérinéales de rattrapage des cancers du canal anal (série consécutive de 95 patients).
  • INTRODUCTION: When radiation therapy fails to control cancer of the anal canal, the only therapeutic alternative is salvage abdomino-perineal resection (APR).
  • CONCLUSION: When anal cancer recurs after radiation therapy, a salvage APR is indicated.

  • Genetic Alliance. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18955923.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


7. Troicki F, Pappas A, Noone R, Denittis A: Radiation therapy of recurrent anal squamous cell carcinoma in-situ: a case report. J Med Case Rep; 2010;4:67

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy of recurrent anal squamous cell carcinoma in-situ: a case report.
  • INTRODUCTION: High-grade anal intraepithelial neoplasia, also referred to as anal squamous carcinoma in-situ, or Bowen's disease of the anus, make up less than 1% of all digestive system cancers in the United States.
  • The treatment of choice is surgical resection with anal mapping.
  • This can compromise the anal sphincter leading to leakage.
  • In this case report, we discuss the efficacy of radiation therapy as a modality to treat post-excisional recurrent Bowen's disease, which may prevent sphincter compromise, leading to improved quality of life.
  • CASE PRESENTATION: An 84-year-old Caucasian woman presented with post-excisional persistent/recurrent squamous cell carcinoma in-situ.
  • The initial lesion measured 3 cm in diameter on the right lateral side of the anal margin.
  • A standard surgery consisting of wide local excision with anal mapping was performed.
  • Our patient recurred with a 1.2 x 0.8 cm lesion on the left anal verge extending to the anal canal.
  • A biopsy along with mapping was done, and 2 of the 17 mapping specimens were positive for carcinoma in-situ, one in the anal canal.
  • Due to the location of the positive anal mapping, and in order to prevent sphincter compromise on re-excision, our patient was offered definitive radiation therapy.
  • Two years after radiation therapy, our patient showed no signs of recurrent disease and had good sphincter control.
  • CONCLUSION: Although the main treatment modality for treating persistent/recurrent Bowen's disease is surgery, an alternative approach using external beam radiation for CIS may be enough to provide a cure for some patients with recurrent disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Australas J Dermatol. 2006 May;47(2):120-3 [16637809.001]
  • [Cites] J Clin Virol. 2005 Mar;32 Suppl 1:S25-33 [15753009.001]
  • [Cites] Swiss Med Wkly. 2003 Jun 28;133(25-26):353-9 [12947531.001]
  • [Cites] Br J Surg. 1997 May;84(5):675-8 [9171763.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 7;87(11):796-802 [7791229.001]
  • [Cites] Urol Clin North Am. 1992 Feb;19(1):83-91 [1310549.001]
  • [Cites] Dis Colon Rectum. 1997 Nov;40(11):1286-93 [9369101.001]
  • (PMID = 20181236.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2841077
  •  go-up   go-down


8. Christensen AF, Nielsen MB, Svendsen LB, Engelholm SA: Three-dimensional anal endosonography may improve detection of recurrent anal cancer. Dis Colon Rectum; 2006 Oct;49(10):1527-32
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional anal endosonography may improve detection of recurrent anal cancer.
  • PURPOSE: In our center since 2001, follow-up examination has included three-dimensional endosonography in all patients with suspicion of local recurrence of anal cancer.
  • METHODS: This prospective study included 38 consecutive patients who have had anal carcinoma and were investigated using three-dimensional endosonography in combination with anoscopy and digital rectal examination at Rigshospitalet from July 2001 to January 2005 under suspicion of local recurrence.
  • CONCLUSIONS: This study indicates that three-dimensional endosonography surpasses two-dimensional endosonography in the evaluation of patients with suspicion of local recurrence of anal cancer especially in combination with anoscopy and digital rectal examination.
  • [MeSH-major] Anal Canal / ultrasonography. Anus Neoplasms / ultrasonography. Endosonography / methods. Imaging, Three-Dimensional. Neoplasm Recurrence, Local / ultrasonography

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16988854.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Schiller DE, Cummings BJ, Rai S, Le LW, Last L, Davey P, Easson A, Smith AJ, Swallow CJ: Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann Surg Oncol; 2007 Oct;14(10):2780-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of salvage surgery for squamous cell carcinoma of the anal canal.
  • BACKGROUND: For patients with anal canal cancer who fail combined modality treatment (CMT), salvage surgery (SS) offers the potential for long term survival.
  • METHODS: We identified 60 patients with persistent or recurrent anal cancer who had undergone SS; 20 were excluded.
  • CONCLUSION: SS for anal canal cancer was associated with significant morbidity.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / pathology. Anal Canal / surgery. Cancer Care Facilities. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Ontario. Registries. Reoperation. Retrospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638059.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Rakoto-Ratsimba HN, Rakototiana AF, Rakotosamimanana J, Ranaivozanany A: [Anal adenocarcinoma revealed by a fistula-in-ano. Report of a case]. Ann Chir; 2006 Nov;131(9):564-6
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal adenocarcinoma revealed by a fistula-in-ano. Report of a case].
  • [Transliterated title] Fistule périanale révélatrice d'un adénocarcinome du canal anal. A propos d'une observation.
  • Anal adenocarcinoma revealed by a fistula-in-ano occurs rarely.
  • Recurrent or non recurrent fistula-in-ano requires multiple biopsies for pathology analysis in order to screen a related cancer.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Anus Neoplasms / complications. Anus Neoplasms / diagnosis. Rectal Fistula / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16712770.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 15
  •  go-up   go-down


11. Mullen JT, Rodriguez-Bigas MA, Chang GJ, Barcenas CH, Crane CH, Skibber JM, Feig BW: Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol; 2007 Feb;14(2):478-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal.
  • BACKGROUND: The standard treatment for epidermoid carcinoma of the anal canal consists of combined radiation and chemotherapy.
  • For patients who present with persistent or locally recurrent disease, salvage abdominoperineal resection is the treatment of choice.
  • RESULTS: Eleven patients underwent radical salvage surgery for persistent disease and 20 patients for recurrent disease.
  • Twelve patients developed recurrent disease after radical salvage surgery.
  • Factors that were not found to have an impact on survival included the presence of persistent versus recurrent disease, tumor (T) stage, and margin status of resection.
  • CONCLUSIONS: Long-term survival following salvage surgery for persistent or locally recurrent epidermoid carcinoma of the anal canal can be achieved in the majority of patients.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17103253.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, Halverson AL: Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States. Ann Surg Oncol; 2008 Jul;15(7):1948-58
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States.
  • BACKGROUND: Over the past two decades, recommended treatment for squamous cell carcinoma of the anal canal has shifted from surgery to primary chemoradiation.
  • Resection is now reserved for persistent or recurrent disease.
  • METHODS: From the National Cancer Data Base (1985-2005), 38,882 patients with anal canal cancer were identified.
  • [MeSH-major] Anus Neoplasms / therapy. Neoplasms, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414951.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Lisi G, Illiceto MT, Rossi C, Broto JM, Jil-Vernet JM, Lelli Chiesa P: Anal canal duplication: a retrospective analysis of 12 cases from two European pediatric surgical departments. Pediatr Surg Int; 2006 Dec;22(12):967-73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal canal duplication: a retrospective analysis of 12 cases from two European pediatric surgical departments.
  • Anal canal duplication (ACD) represents an extremely rare intestinal congenital anomaly of unknown origin.
  • The confirmative diagnosis is histopathological, with evidence of an anal mucosal lining (squamous +/- transitional epithelium), surrounded from a smooth muscle coat and anal glands.
  • According to clinical presentation, patients could be divided in three age groups: asymptomatic (mean age 4.8 months, six patients - one with an associated complex genitourinary malformation, one with a presacral mature teratoma, one with ACD evidenced hysthologically on a retroanal mass removed during the correction of an ARM), mildly symptomatic - constipation, mucous discharge (mean age 29.2 months, four patients - one with associated presacral ependymoma and intestinal neuronal dysplasia type B, one with presacral mass) and complicated - perineal abscess, recurrent fistula (mean age 34 months, two patients).
  • Surgical early removal (mucosectomy or perineal/posterior sagittal approach, depending on length of ACD and associated presacral mass) is warranted, also in asymptomatic patients, because of the risk of inflammatory complications and cancer (the latter reported in literature in adults).
  • [MeSH-major] Anal Canal / abnormalities. Anal Canal / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17061104.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


14. You YN, Larson DW, Dozois EJ, Nelson H, Antpack Filho E, Klein K, Miller RC: Multimodality salvage therapy for anal cancer failing standard chemoradiation. J Clin Oncol; 2009 May 20;27(15_suppl):e15635

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality salvage therapy for anal cancer failing standard chemoradiation.
  • : e15635 Background: Most squamous cell carcinomas of the anal canal (SCC) respond to chemoradiation, but effective therapy for locally-invasive(T4) or recurrent disease that fails standard chemoradiation and/or salvage abdominoperineal resection (APR) has not been clearly delineated.
  • METHODS: A prospective registry including 26 patients with locally-invasive or recurrent disease treated between 1993 and 2007 was reviewed.
  • Five-year OS were: 50%, 10%, and 22% for patients with locally-invasive, recurrent, and re-recurrent disease respectively.
  • CONCLUSIONS: For select patients with locally-persistent or recurrent SCC who fail standard primary treatment, a multimodality approach involving chemoradiation, extended pelvic resection and IORT offers a chance for improved survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962742.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Subramonia Iyer S, Akl A: A review of the outcomes of patients with anal cancer enrolled in the Hurley Cancer Registry: 1987-2004. J Clin Oncol; 2009 May 20;27(15_suppl):e15131

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A review of the outcomes of patients with anal cancer enrolled in the Hurley Cancer Registry: 1987-2004.
  • : e15131 Background: This paper describes the outcomes of patients with anal cancer enrolled in the Hurley Cancer Registry.
  • The Hurley cancer registry was searched using diagnosis codes for anal cancer.
  • The records retrieved, were reviewed for demographic and pathologic details,cancer recurrence, and vital status at last follow up.
  • RESULTS: Over a period of 18 years (1987 - 2004), there were 36 patients enrolled in the registry, with a diagnosis of anal cancer.
  • Five patients (14%) developed recurrent disease during follow up, after a median of 1.8 years (range: 0.67- 4.2 years).
  • Three of the five (60%) recurrent cancers were associated with HIV infection.
  • CONCLUSIONS: Among patients in the Hurley Cancer Registry, 1.
  • Squamous cell carcinoma is the commonest (75%) anal cancer.
  • 2. The risk of recurrence of anal cancer was 14% over 6-years, and 80% of recurrence was localised to the anal canal.
  • This was 78.9% for the subgroup of patients without recurrence, and 86.1% for the subgroup with recurrent disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960904.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Heyn J, Placzek M, Ozimek A, Baumgaertner AK, Siebeck M, Volkenandt M: Malignant melanoma of the anal region. Clin Exp Dermatol; 2007 Sep;32(5):603-7
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma of the anal region.
  • Malignant melanoma (MM) of the anal region is an uncommon disease.
  • Anorectal melanomas (AM) are most common in the rectum, followed by the anal canal and anal verge.
  • We report on a 39-year old man who presented with a 5-week history of recurrent prolapse of an anal tumour.
  • [MeSH-major] Anus Neoplasms. Melanoma
  • [MeSH-minor] Adult. Angiogenesis Inhibitors / therapeutic use. Cancer Vaccines / therapeutic use. Diagnosis, Differential. Humans. Interferon-alpha / therapeutic use. Male. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17376215.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Cancer Vaccines; 0 / Interferon-alpha
  • [Number-of-references] 25
  •  go-up   go-down


17. Stewart D, Yan Y, Kodner IJ, Birnbaum E, Fleshman J, Myerson R, Dietz D: Salvage surgery after failed chemoradiation for anal canal cancer: should the paradigm be changed for high-risk tumors? J Gastrointest Surg; 2007 Dec;11(12):1744-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage surgery after failed chemoradiation for anal canal cancer: should the paradigm be changed for high-risk tumors?
  • It is common belief that patients failing chemoradiation therapy (CRT) for squamous cell cancer of the anus (SCCA) can be salvaged with subsequent surgery.
  • The aim of this study was to examine our experience with abdominoperineal resection (APR) in cases of persistent or recurrent SCCA with an emphasis on survival and morbidity.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Salvage Therapy


18. Hogg ME, Popowich DA, Wang EC, Kiel KD, Stryker SJ, Halverson AL: HIV and anal cancer outcomes: a single institution's experience. Dis Colon Rectum; 2009 May;52(5):891-7
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV and anal cancer outcomes: a single institution's experience.
  • PURPOSE: The purpose of this study is to identify the effect of HIV status on outcome of treatment for squamous-cell carcinoma of the anal canal.
  • METHODS: A retrospective review was performed on all patients with squamous-cell carcinoma of the anal canal treated at a single academic institution between January 1996 and December 2006.
  • RESULTS: Our search identified 87 (21 HIV-positive) patients who had invasive squamous-cell cancer.
  • Eight percent of HIV-negative and 29 percent of HIV-positive patients developed recurrent disease after 6 months (P = 0.0009).
  • [MeSH-major] Anus Neoplasms / mortality. Carcinoma, Squamous Cell / mortality. HIV Infections / mortality


19. Uchikoshi F, Nishida T, Ueshima S, Nakahara M, Matsuda H: Laparoscope-assisted anal sphincter-preserving operation preceded by transanal procedure. Tech Coloproctol; 2006 Mar;10(1):5-9; discussion 9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscope-assisted anal sphincter-preserving operation preceded by transanal procedure.
  • BACKGROUND: Transanal intersphincteric resection (ISR) was introduced and has been increasingly performed as an ultimate surgical treatment for extremely low rectal cancer.
  • METHODS: Between December 2003 and June 2004, we performed laparoscope-assisted ISR for two patients with very low rectal cancer and total colectomy for two patients with ulcerative colitis complicated by colorectal cancer.
  • All patients showed favorable recovery including postoperative anal function with no complication or recurrent disease.
  • CONCLUSIONS: This procedure is feasible and has favorable short-term results for radical treatment of very low rectal disease, while preserving anal function.
  • [MeSH-major] Anal Canal / surgery. Proctoscopy. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16528490.001).
  • [ISSN] 1123-6337
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


20. Weiser MR, Landmann RG, Wong WD, Shia J, Guillem JG, Temple LK, Minsky BD, Cohen AM, Paty PB: Surgical salvage of recurrent rectal cancer after transanal excision. Dis Colon Rectum; 2005 Jun;48(6):1169-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical salvage of recurrent rectal cancer after transanal excision.
  • PURPOSE: This study examines surgical salvage of locally recurrent rectal cancer following transanal excision of early tumors.
  • METHODS: Through retrospective review of a colorectal database we identified 50 patients who underwent attempted surgical salvage for local recurrence following initial transanal excision of T1 or T2 rectal cancer.
  • CONCLUSION: Pelvic recurrence following transanal excision of early rectal cancer is often locally advanced, requiring an extended pelvic dissection with en bloc resection of adjacent pelvic organs to achieve salvage.
  • When contemplating local excision for early rectal cancer, the risk of local recurrence, the extent and morbidity of surgery required for salvage, and the modest cure rate following salvage should be considered.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Colectomy. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Pelvic Exenteration. Reoperation. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15793645.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Lee J, Corman M: Recurrence of anal adenocarcinoma after local excision and adjuvant chemoradiation therapy: report of a case and review of the literature. J Gastrointest Surg; 2009 Jan;13(1):150-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of anal adenocarcinoma after local excision and adjuvant chemoradiation therapy: report of a case and review of the literature.
  • INTRODUCTION: Tumors arising from the anal canal are rare, comprising 1.5% of all gastrointestinal tumors in the USA.
  • The vast majority of these anal cancers are epidermoid (cloacogenic/basaloid and squamous cell carcinomas), while adenocarcinomas reportedly occur 5% to 19% of the time.
  • Because of its rarity, reports about anal adenocarcinoma are limited to small retrospective studies and case reports.
  • Moreover, no series has directly compared outcomes between patients undergoing the various available treatment options, making it difficult to determine the optimal treatment for this aggressive cancer.
  • Current management of this cancer remains controversial, with some authors believing abdominoperineal resection with permanent colostomy should be considered the standard treatment.
  • CASE PRESENTATION: We describe a case of recurrent anal adenocarcinoma after conservative management with local excision and adjuvant chemoradiation therapy.
  • [MeSH-major] Adenocarcinoma / surgery. Antineoplastic Agents / therapeutic use. Anus Neoplasms / pathology. Anus Neoplasms / therapy. Colectomy / methods

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18810561.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


22. Zampino MG, Magni E, Sonzogni A, Renne G: K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment? Cancer Chemother Pharmacol; 2009 Dec;65(1):197-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment?
  • PURPOSE: Squamous cell anal carcinoma (SCC) is an uncommon disease comprising only 1-5% of all intestinal tumours.
  • The EGFR status and k-ras mutations in SCC of the anal canal has not been well investigated.
  • This observation previously reported in other tumours has supported the effective use of EGFR-inhibitors in recurrent or metastatic disease.
  • [MeSH-major] Anus Neoplasms / genetics. Carcinoma, Squamous Cell / genetics. Proto-Oncogene Proteins / genetics. Receptor, Epidermal Growth Factor / genetics. ras Proteins / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19727729.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


23. Handisurya A, Rieger A, Bago-Horvath Z, Schellenbacher C, Bankier A, Salat A, Stingl G, Kirnbauer R: Rapid progression of an anal Buschke-Lowenstein tumour into a metastasising squamous cell carcinoma in an HIV-infected patient. Sex Transm Infect; 2009 Aug;85(4):261-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid progression of an anal Buschke-Lowenstein tumour into a metastasising squamous cell carcinoma in an HIV-infected patient.
  • BACKGROUND: Buschke-Löwenstein tumour (BLT) of the anogenitalia is a locally invasive, destructively growing verrucous carcinoma that does not metastasise.
  • Nevertheless, the tumour grows relentlessly and may rarely progress into squamous cell cancer (SCC).
  • RESULTS: A human immunodeficiency virus (HIV)-infected immunosuppressed patient developed (peri)anal warts accompanied by recurrent abscesses and fistulae.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / secondary. HIV Infections / complications. Immunocompromised Host
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / virology. Anti-HIV Agents / therapeutic use. Cachexia / etiology. Fatal Outcome. Groin. HIV Seropositivity / drug therapy. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness


24. Uemura M, Ikeda M, Sekimoto M, Haraguchi N, Mizushima T, Yamamoto H, Takemasa I, Ishii H, Mori M: Prevention of severe pelvic abscess formation following extended radical surgery for locally recurrent rectal cancer. Ann Surg Oncol; 2009 Aug;16(8):2204-10
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of severe pelvic abscess formation following extended radical surgery for locally recurrent rectal cancer.
  • BACKGROUND: For treatment of locally recurrent rectal cancer (LRRC), extended radical surgery is sometimes required to obtain a negative margin.
  • The aim of this study was to determine the effects of reconstructive surgery using a large rectus abdominis myocutaneous (RAM) flap and anal preservation surgery on the incidence of severe PA.
  • To reduce the risk of infections, we modified the surgical approach after 2004 to include a larger volume of RAM flap (modified RAM flap) and implemented anal preservation surgery.
  • The incidence of severe PA was lower in the anal preservation group [1 of 12 (8.3%)] compared with those who did not undergo such surgery [14 of 32 (44%), P = 0.035].
  • All three patients who underwent anal preservation and modified RAM flap reconstruction did not develop severe PA.
  • Multiple logistic analysis identified no anal preservation (Odds ratio [OR] = 10.6) and performing of sacrectomy (OR = 20.0) as risk factors for severe PA.
  • CONCLUSION: Anal preservation surgery is an effective measure against the development of severe PA after radical resection of LRRC.
  • [MeSH-minor] Adult. Aged. Anal Canal / surgery. Female. Humans. Male. Middle Aged. Wound Healing

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Abscess.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19506961.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Christoforidis D, Cho HM, Dixon MR, Mellgren AF, Madoff RD, Finne CO: Transanal endoscopic microsurgery versus conventional transanal excision for patients with early rectal cancer. Ann Surg; 2009 May;249(5):776-82
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic microsurgery versus conventional transanal excision for patients with early rectal cancer.
  • OBJECTIVE: To compare transanal endoscopic microsurgery (TEMS) with conventional transanal excision (TAE) in terms of the quality of resection, local recurrence, and survival rates in patients with stage I rectal cancer.
  • We excluded patients with node-positive, metastatic, recurrent, previously irradiated, or snare-excised tumors.
  • In the TAE group, 52 (40%) of tumors were <5 cm from the anal verge (AV); in the TEMS group, only 1 (2%) (P = 0.0001).
  • In our multivariate analysis, the tumor distance from the anal verge, the resection margin status, the T stage, and the use of adjuvant therapy--but not the surgical technique (i.e., TEMS or TAE) itself--were independent predictors of local recurrence and DFS.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Female. Humans. Male. Microsurgery. Middle Aged. Patient Selection. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19387326.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


26. Hamada M, Ozaki K, Iwata J, Nishioka Y, Horimi T: A case of rectosigmoid cancer metastasizing to a fistula in ano. Jpn J Clin Oncol; 2005 Nov;35(11):676-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of rectosigmoid cancer metastasizing to a fistula in ano.
  • We herein report a case of rectosigmoid cancer metastasizing to a fistula in ano.
  • A 53-year-old man complaining of anal bleeding consulted another hospital.
  • He had been suffering from an anal fistula since 7 years.
  • On the left upper side of the skin surface around the anus a fistula end was seen as a hole that tunneled down into the back passage, although no hard tumor was palpable on the hole.
  • The post-operative pathological diagnosis was rectosigmoid cancer, Type 2, T2, N0, M0, stage II.
  • The anal fistula was a simple type and mucinous discharge was not observed.
  • On 23 February 2004, coring out the anal fistula was performed by the former hospital.
  • We diagnosed this tumor as metastatic adenocarcinoma from a rectosigmoid cancer.
  • Recurrent lesions were not seen during the first year after the first operation.
  • [MeSH-major] Adenocarcinoma / secondary. Anus Neoplasms / secondary. Rectal Fistula / pathology. Rectal Neoplasms / pathology. Sigmoid Neoplasms / pathology
  • [MeSH-minor] Anal Canal / pathology. Humans. Lymph Node Excision. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16275674.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


27. Nelson RS, Boland E, Ewing BM, Blatchford GJ, Ternent C, Shashidharan M, Tran NA, Beaty J, Thorson AG: Permanent diversion rates after neoadjuvant therapy and coloanal anastomosis for rectal cancer. Am J Surg; 2009 Dec;198(6):765-70
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Permanent diversion rates after neoadjuvant therapy and coloanal anastomosis for rectal cancer.
  • BACKGROUND: The aim of this study was to assess the rate of permanent diversion in patients undergoing coloanal anastomosis after neoadjuvant therapy for rectal cancer.
  • METHODS: We performed a retrospective review of patients with rectal cancer who underwent a total mesorectal excision of a tumor within 9 cm of the anal verge.
  • The average tumor distance from the anal verge was 7 cm (range, 4-9 cm).
  • Twenty-five patients (12%) had recurrent disease, 16 of these were local recurrence.
  • [MeSH-major] Anal Canal / surgery. Colon / surgery. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19969127.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Stipa F, Burza A, Lucandri G, Ferri M, Pigazzi A, Ziparo V, Casula G, Stipa S: Outcomes for early rectal cancer managed with transanal endoscopic microsurgery: a 5-year follow-up study. Surg Endosc; 2006 Apr;20(4):541-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes for early rectal cancer managed with transanal endoscopic microsurgery: a 5-year follow-up study.
  • BACKGROUND: This study aimed to evaluate the long-term risk of local and distant recurrence as well as the survival of patients with early rectal cancer treated using transanal endoscopic microsurgery (TEM).
  • METHODS: The study reviewed 69 patients with Tis/T1/T2 rectal cancer treated using full-thickness excision between 1991 and 1999.
  • The overall cancer-related mortality rate was 7.2%.
  • CONCLUSIONS: After local excision of early rectal cancer, a substantial local recurrence rate is observed.
  • Patients with recurrent Tis/T1 cancers who undergo a salvage operation may achieve good long-term outcome.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Postoperative Care. Preoperative Care. Radiotherapy, Adjuvant. Reoperation. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16508812.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


29. Saito N, Suzuki T, Sugito M, Ito M, Kobayashi A, Tanaka T, Kotaka M, Karaki H, Kobatake T, Tsunoda Y, Shiomi A, Yano M, Minagawa N, Nishizawa Y: Bladder-sparing extended resection of locally advanced rectal cancer involving the prostate and seminal vesicles. Surg Today; 2007;37(10):845-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder-sparing extended resection of locally advanced rectal cancer involving the prostate and seminal vesicles.
  • PURPOSE: Total pelvic exenteration (TPE) is the standard procedure for locally advanced rectal cancer involving the prostate and seminal vesicles.
  • METHODS: Eleven patients with advanced primary or recurrent rectal cancer involving the prostate or seminal vesicles, or both, underwent bladder-sparing extended colorectal resection with radical prostatectomy.
  • Local control and urinary and anal function were evaluated postoperatively.
  • Coloanal or colo-anal canal anastomosis was also performed in four patients.
  • CONCLUSION: These bladder-sparing procedures allow conservative surgery to be performed in selected patients with advanced rectal cancer involving the prostate or seminal vesicles, without compromising local control.


30. Pizzocaro G, Algaba F, Horenblas S, Solsona E, Tana S, Van Der Poel H, Watkin NA, European Association of Urology (EAU) Guidelines Group on Penile Cancer: EAU penile cancer guidelines 2009. Eur Urol; 2010 Jun;57(6):1002-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EAU penile cancer guidelines 2009.
  • CONTEXT: Squamous cell carcinoma (SCC) of the penis is a relatively rare but ominous disease.
  • Similarities in etiology with SCC of the head and neck, the female genitalia, and the anal canal have been found.
  • Adjuvant and neoadjuvant chemotherapy showed promising results in patients with advanced or recurrent disease.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Penile Neoplasms / diagnosis. Penile Neoplasms / therapy. Quality of Life / psychology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20163910.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] Switzerland
  •  go-up   go-down


31. Mureşan M, Bancu S, Bara T, Bancu L, Turcu M, Mureşan S: [Local recurrence after the sphincter-saving operations and abdominal perineal resection in rectal cancer]. Chirurgia (Bucur); 2009 Jul-Aug;104(4):415-8
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Local recurrence after the sphincter-saving operations and abdominal perineal resection in rectal cancer].
  • By local recurrence we define the appearance of the same anatomopathological type of cancer like the one initially described in the primary tumor, limited at the rectum or pelvis.The study is based on the analysis of all the cases with rectal cancer who undergone surgical procedures in Surgical Clinic No.2 Tg.
  • Using the most important parameters for each patient we identified some risk factors for the recurrence of the rectal cancer: surgical procedures--there were no major variations in the local recurrence between the sphincter-saving operations and abdominal perineal resections.
  • The recurrent rectal cancer is more frequent in aged patients with high aggressive adenocarcinomas.
  • [MeSH-major] Abdomen / surgery. Adenocarcinoma / surgery. Anal Canal. Neoplasm Recurrence, Local / surgery. Perineum / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Mucinous / surgery. Aged. Carcinoma, Squamous Cell / surgery. Digestive System Surgical Procedures / methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886048.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


32. Sakakura C, Nishio M, Miyagawa K, Miyashita A, Nagata H, Kin S, Fukuda K, Nakase Y, Hagiwara A, Nakanishi M, Yamazaki J, Yoshikawa S, Okamoto K, Kokuba Y, Otsuji E: Laparoscope-assisted superlow anterior resection combined with inter sphincteric rectal dissection for very low advanced rectal cancers combined with preoperative chemotherapy. Hepatogastroenterology; 2009 May-Jun;56(91-92):692-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transanal intersphincteric resection (ISR) has been increasingly used as a surgical treatment for extremely low rectal cancer.
  • The patient was a 46-year-old male with advanced rectal cancer on the lower rectum adjacent to the dentate line.
  • This patient showed favorable recovery including postoperative anal function with no complications or recurrent disease.
  • This procedure is feasible and has favorable short-term results for the radical treatment of very low rectal disease, while preserving anal function.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Antineoplastic Agents / therapeutic use. Dissection / methods. Laparoscopy. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19621682.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


33. Doornebosch PG, Ferenschild FT, de Wilt JH, Dawson I, Tetteroo GW, de Graaf EJ: Treatment of recurrence after transanal endoscopic microsurgery (TEM) for T1 rectal cancer. Dis Colon Rectum; 2010 Sep;53(9):1234-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrence after transanal endoscopic microsurgery (TEM) for T1 rectal cancer.
  • PURPOSE: The aim of this study was to evaluate the management and outcome of local recurrences after transanal endoscopic microsurgery for T1 rectal cancer.
  • METHODS: Consecutive patients who underwent transanal endoscopic microsurgery for pT1 rectal cancer at a Dutch referral center (IJsselland Hospital) were registered in a prospective database.
  • Follow-up was according to Dutch guidelines on rectal cancer, with additional rigid rectoscopy and endorectal ultrasound examinations every 3 months for the first 2 years, and every 6 months thereafter.
  • RESULTS: Of a total of 88 patients who underwent transanal endoscopic microsurgery for pT1 rectal cancer, 18 patients (20.5%) had a local recurrence.
  • At 3 years, overall survival was 31%; cancer-related survival was 58%.
  • CONCLUSIONS: Recurrent disease after transanal endoscopic microsurgery for T1 rectal cancer is a major problem.
  • [MeSH-minor] Aged. Aged, 80 and over. Anal Canal. Endosonography. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Salvage Therapy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dis Colon Rectum. 2010 Sep;53(9):1231-3 [20706064.001]
  • (PMID = 20706065.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Zbar AP, Shenoy RK, Chiappa A: Extended abdominoperineal resection in women: the Barbadian experience. Int Semin Surg Oncol; 2007;4:1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVES: We report our results of a selective approach to primary direct appositional vaginal repair versus transverse rectus abdominis flap repair (TRAM) in patients with extensive rectal/anal cancer or in cases with primary cancer of cervix, vagina or vulva involving the anal canal and anal sphincters.
  • Exenterative procedures were performed in 2 cases of primary vaginal cancer, following Wertheim hysterectomy for carcinoma of the cervix with recurrence after radiation and in 2 further cases of anal cancer with extensive pelvic recurrence after primary chemoradiation.
  • Fifteen cases are alive on follow-up with no evidence of disease; 2 patients who had recurrent carcinoma of the cervix and who underwent TRAM flap reconstruction, have recurrent disease after 5 and 6 months of follow-up, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2005 May;97(2):596-601 [15863165.001]
  • [Cites] Cancer. 1996 Nov 15;78(10):2229-35 [8918419.001]
  • [Cites] Am Surg. 2005 Feb;71(2):117-22 [16022009.001]
  • [Cites] Br J Surg. 2005 Aug;92(8):1046 [16034808.001]
  • [Cites] Ann Surg Oncol. 2005 Feb;12(2):104-10 [15827789.001]
  • [Cites] Br J Surg. 2005 Apr;92(4):482-6 [15736219.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):438-43 [15719190.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):476-81; discussion 481-2 [15714245.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2005 Sep-Oct;16(5):389-94 [15657636.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):398-403 [15297179.001]
  • [Cites] Gynecol Oncol. 2004 Jun;93(3):610-4 [15196852.001]
  • [Cites] World J Gastroenterol. 2004 Feb 1;10(3):424-6 [14760771.001]
  • [Cites] Ann Surg Oncol. 2004 Jan;11(1):27-33 [14699030.001]
  • [Cites] Dis Colon Rectum. 2003 Dec;46(12):1619-25 [14668586.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):39-45 [12468340.001]
  • [Cites] Cancer. 2002 Sep 1;95(5):1144-50 [12209702.001]
  • [Cites] Dis Colon Rectum. 2002 Feb;45(2):239-45; discussion 245-8 [11852339.001]
  • [Cites] Arch Surg. 1990 Oct;125(10):1371-6; discussion 1376-7 [2222178.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Plast Reconstr Surg. 1983 Dec;72(6):751-65 [6647599.001]
  • [Cites] Dis Colon Rectum. 1994 Sep;37(9):890-6 [8076488.001]
  • [Cites] Gynecol Oncol. 2006 May;101(2):261-8 [16426668.001]
  • [Cites] Int J Gynecol Cancer. 2005 May-Jun;15(3):542-8 [15882183.001]
  • (PMID = 17214895.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1779795
  •  go-up   go-down


35. Chrysos E, Athanasakis E, Vrekousis T, Almarashdah S, Fiorentini G, Xynos E, Zoras O: Abdominal and pelvic stop-flow chemotherapy. Effect of chemotherapeutic agents and tissue ischemia on rectoanal pressures. J Exp Clin Cancer Res; 2006 Sep;25(3):303-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stationary rectoanal manometry was performed within 24 hrs before and repeated 48 hrs after stop-flow chemotherapy in 7 consecutive patients with a history of locally advanced or recurrent abdominal and pelvic tumors.
  • Anal sphincter resting and squeeze pressures, rectal sensitivity, rectoanal inhibitory reflex and rectal volumes at which temporary and permanent urge to defecate were reported were examined.
  • Intraoperatively, changes in rectal and anal resting pressures before, during and after occlusion of the vessels and after administration of chemotherapeutic agent were as well recorded, analyzed and interpreted using ambulatory manometry.
  • Induction of anesthesia reduced distal and proximal anal resting pressures.
  • Intraoperative administration of chemotherapy did not further affect anal resting pressures during or after hypoxia.
  • Tissue hypoxia induced by vascular occlusion during stop-flow chemotherapy procedure, seems to be the only factor leading to a dramatic drop of anal pressures.
  • Anal pressures fully recover after reperfusion of the isolated area.
  • [MeSH-major] Abdominal Neoplasms / drug therapy. Anal Canal / drug effects. Antineoplastic Agents / pharmacokinetics. Chemotherapy, Cancer, Regional Perfusion / methods. Ischemia / pathology. Pelvic Neoplasms / drug therapy. Rectum / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17167968.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


36. Chirica M, Parc Y, Tiret E, Dehni N, McNamara D, Parc R: Coloanal sleeve anastomosis (Soave procedure): the ultimate treatment option for complex rectourinary fistulas. Dis Colon Rectum; 2006 Sep;49(9):1379-83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four fistulas were the result of radical prostatectomy and four followed anterior resection for rectal cancer after radiochemotherapy.
  • One patient required ileal pouch-anal anastomosis on postoperative Day 1 because of necrosis of the descended colon.
  • Two patients had recurrent fistulas at two and three months respectively.
  • One patient had moderate problems with this recurrent fistula and had his stoma closed, but the other patient required a permanent ileostomy.
  • [MeSH-major] Anal Canal / surgery. Colon / surgery. Rectal Fistula / surgery. Urinary Fistula / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16819570.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Speake D, Lees N, McMahon RF, Hill J: Who should be followed up after transanal endoscopic resection of rectal tumours? Colorectal Dis; 2008 May;10(4):330-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 35 who went on to long-term follow-up post-TEM (0.6-8.1 years, median 4) four developed recurrent cancer (two local with submucosal disease and two liver metastases).
  • [MeSH-major] Adenoma. Carcinoma. Endoscopy, Gastrointestinal / methods. Microsurgery / methods. Neoplasm Recurrence, Local / prevention & control. Rectal Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Case-Control Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18190616.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


38. Patel CB, Ramos-Valadez DI, Haas EM: Robotic-assisted laparoscopic abdominoperineal resection for anal cancer: feasibility and technical considerations. Int J Med Robot; 2010 Dec;6(4):399-404
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robotic-assisted laparoscopic abdominoperineal resection for anal cancer: feasibility and technical considerations.
  • BACKGROUND: Robotic-assisted laparoscopic surgery is an emerging technology that may prove advantageous for complex colorectal procedures involving the irradiated pelvis, such as abdominoperineal resection for recurrent anal cancer.
  • METHODS: Over a 6 month period, five abdominoperineal resections were performed using the da Vinci® robot for recurrent anal cancer in patients initially treated with definitive chemoradiation therapy.
  • CONCLUSION: Robotic-assisted laparoscopic surgery for anal cancer was found to be a safe and feasible procedure.
  • [MeSH-major] Abdomen / surgery. Anus Neoplasms / surgery. Laparoscopy / methods. Perineum / surgery. Robotics / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • (PMID = 20827795.001).
  • [ISSN] 1478-596X
  • [Journal-full-title] The international journal of medical robotics + computer assisted surgery : MRCAS
  • [ISO-abbreviation] Int J Med Robot
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


39. Giuliano AR, Anic G, Nyitray AG: Epidemiology and pathology of HPV disease in males. Gynecol Oncol; 2010 May;117(2 Suppl):S15-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, recurrent respiratory papillomatosis is a rare disease most often associated with HPV types 6 and 11.
  • For example, there is increasing incidence of anal cancer in western countries; however, there are limited data on its primary cause, anal canal HPV infection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Inc.
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2883-91 [18980292.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2841-54 [18980203.001]
  • [Cites] J Infect Dis. 2009 Feb 1;199(3):362-71 [19133808.001]
  • [Cites] Int J Cancer. 2009 Mar 15;124(6):1251-7 [19089913.001]
  • [Cites] J Clin Virol. 2009 Feb;44(2):111-4 [19097933.001]
  • [Cites] World J Urol. 2009 Apr;27(2):141-50 [18607597.001]
  • [Cites] Eur J Cancer Prev. 2009 Jun;18(3):236-9 [19491611.001]
  • [Cites] Int J STD AIDS. 2009 Aug;20(8):557-60 [19625588.001]
  • [Cites] Sex Transm Infect. 2009 Sep;85(5):330-5 [19342375.001]
  • [Cites] J Clin Pathol. 2009 Oct;62(10):870-8 [19706632.001]
  • [Cites] Sex Transm Infect. 2009 Dec;85(7):499-502 [19837728.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Cancer Causes Control. 2001 Apr;12(3):267-77 [11405332.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1211-8 [11583947.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1105-12 [11948269.001]
  • [Cites] J Infect Dis. 2002 Aug 15;186(4):462-9 [12195372.001]
  • [Cites] Clin Infect Dis. 2002 Oct 15;35(Suppl 2):S210-24 [12353208.001]
  • [Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]
  • [Cites] Clin Infect Dis. 2003 Jun 1;36(11):1397-403 [12766834.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] JAMA. 1982 Apr 9;247(14):1988-90 [7062503.001]
  • [Cites] Lancet. 1985 Apr 27;1(8435):943-6 [2859410.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] Br Med J (Clin Res Ed). 1987 Nov 21;295(6609):1306-8 [3120988.001]
  • [Cites] J Natl Cancer Inst. 1989 Nov 15;81(22):1726-31 [2810388.001]
  • [Cites] Int J Cancer. 1990 Aug 15;46(2):178-84 [2384268.001]
  • [Cites] Int J Cancer. 1991 Feb 20;47(4):504-9 [1995481.001]
  • [Cites] J Natl Cancer Inst. 1993 Jan 6;85(1):19-24 [8380060.001]
  • [Cites] BMJ. 1993 Feb 13;306(6875):419-22 [8461721.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] J Infect Dis. 1994 Sep;170(3):682-5 [8077728.001]
  • [Cites] Genitourin Med. 1994 Aug;70(4):240-6 [7959707.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1995 Dec;121(12):1386-91 [7488368.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 7;88(15):1068-75 [8683638.001]
  • [Cites] J Infect Dis. 1997 Aug;176(2):353-61 [9237700.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] J Infect Dis. 2004 Dec 15;190(12):2070-6 [15551204.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75 [15734974.001]
  • [Cites] J Clin Virol. 2005 Mar;32 Suppl 1:S82-90 [15753016.001]
  • [Cites] Int J Cancer. 2005 Sep 10;116(4):606-16 [15825185.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):451-5 [16280701.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/11-25 [16949997.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/35-41 [16950016.001]
  • [Cites] J Infect Dis. 2006 Oct 15;194(8):1044-57 [16991079.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1107-14 [17548671.001]
  • [Cites] J Infect Dis. 2007 Oct 15;196(8):1128-36 [17955430.001]
  • [Cites] J Infect Dis. 2007 Oct 15;196(8):1137-45 [17955431.001]
  • [Cites] J Infect Dis. 2007 Oct 15;196(8):1146-52 [17955432.001]
  • [Cites] J Infect Dis. 2007 Nov 15;196(10):1447-54 [18008222.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2008 Feb;265(2):147-51 [18046565.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):612-9 [18235120.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2007;90:1-636 [18354839.001]
  • [Cites] Sex Transm Dis. 2008 Apr;35(4):357-60 [18360316.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2 Suppl 1):S6-13 [18499914.001]
  • [Cites] J Infect Dis. 2008 Jun 15;197(12):1676-84 [18426367.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2036-43 [18708396.001]
  • [Cites] J Infect Dis. 2008 Sep 15;198(6):827-35 [18657037.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2683-91 [18843010.001]
  • [Cites] J Infect Dis. 2009 Jan 1;199(1):7-13 [19086813.001]
  • (PMID = 20138345.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098803; United States / NCI NIH HHS / CA / R03 CA134204; United States / NCI NIH HHS / CA / R01CA098803; United States / NCI NIH HHS / CA / R03CA134204-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS645179; NLM/ PMC4254924
  •  go-up   go-down


40. Vorob'ev GI, Shelygin IuA, Nechushkin MI, Rybakov EG: [Results of surgical treatment of residual and recurrent anal tumors]. Khirurgiia (Mosk); 2008;(8):4-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of surgical treatment of residual and recurrent anal tumors].
  • Radio- or chemotherapy is a modern standard of anal cancer treatment.
  • The study is aimed to evaluate the role of abdominoperineal resection in the treatment of residual and recurrent anal cancer.
  • The complete tumor regression after radiotherapy/radiochemotherapy was achieved in 74(61.1%) of 120 patients with cancer-specific survival rate of 81.7%.
  • Thus, abdominoperineal resection remains the method of choice in the treatment of residual and recurrent anal tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18833142.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


41. Nappi C, Di Spiezio Sardo A, Mandato VD, Bifulco G, Merello E, Savanelli A, Mignogna C, Capra V, Guida M: Leiomyomatosis peritonealis disseminata in association with Currarino syndrome? BMC Cancer; 2006;6:127

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE PRESENTATION: A 27 year-old patient referred to our gynaecology unit for pelvic pain, amenorrhoea, stress incontinence, chronic constipation and recurrent intestinal and urinary infections.
  • [MeSH-minor] Actins / analysis. Adult. Anal Canal / abnormalities. Female. Humans. Immunohistochemistry. Receptors, Steroid / analysis. Rectum / abnormalities. Sacrum / abnormalities. Syndrome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynaecol Obstet. 2000 Mar;68(3):271-2 [10699204.001]
  • [Cites] Am J Clin Pathol. 1978 Apr;69(4):452-7 [645645.001]
  • [Cites] Am J Hum Genet. 2000 May;66(5):1504-15 [10749657.001]
  • [Cites] Obstet Gynecol. 2000 Jun;95(6 Pt 2):1009-11 [10808006.001]
  • [Cites] J Am Coll Surg. 2000 Aug;191(2):212-5 [10945368.001]
  • [Cites] Arch Gynecol Obstet. 2000 Sep;264(2):97-8 [11045333.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(2):173-5 [2114697.001]
  • [Cites] Am J Obstet Gynecol. 1990 Aug;163(2):591-3 [2386147.001]
  • [Cites] Br J Surg. 1991 May;78(5):536-8 [2059799.001]
  • [Cites] Am J Obstet Gynecol. 1992 Jan;166(1 Pt 1):167-8 [1733191.001]
  • [Cites] Acta Oncol. 1991;30(8):987-8 [1777251.001]
  • [Cites] Am J Obstet Gynecol. 1992 Aug;167(2):515-6 [1497063.001]
  • [Cites] BJOG. 2001 Jun;108(6):661-4 [11426907.001]
  • [Cites] Int J Gynecol Pathol. 2001 Jul;20(3):267-70 [11444203.001]
  • [Cites] Int J Gynecol Cancer. 2001 Jul-Aug;11(4):312-5 [11520371.001]
  • [Cites] Eur J Hum Genet. 2001 Aug;9(8):599-605 [11528505.001]
  • [Cites] Int J Gynecol Pathol. 1999 Jul;18(3):259-64 [12090595.001]
  • [Cites] Pathol Int. 2003 Mar;53(3):179-85 [12608900.001]
  • [Cites] J Pediatr Surg. 2003 Jul;38(7):1086-9 [12861546.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2003 Dec 10;111(2):216-8 [14597256.001]
  • [Cites] J Pediatr Surg. 2004 Sep;39(9):1305-11 [15359381.001]
  • [Cites] Can J Surg. 1993 Feb;36(1):46-8 [8443717.001]
  • [Cites] Neurosurgery. 1993 May;32(5):755-78; discussion 778-9 [8492851.001]
  • [Cites] Am J Obstet Gynecol. 1993 Jul;169(1):52-4 [8333475.001]
  • [Cites] Acta Obstet Gynecol Scand. 1994 Jan;73(1):81-3 [8304036.001]
  • [Cites] Pathol Res Pract. 1994 May;190(5):500-4; discussion 504-6 [7991470.001]
  • [Cites] Semin Pediatr Surg. 1995 Feb;4(1):35-47 [7728507.001]
  • [Cites] Nat Genet. 1995 Sep;11(1):93-5 [7550324.001]
  • [Cites] Gynecol Oncol. 1996 May;61(2):272-4 [8626146.001]
  • [Cites] J Reprod Med. 1996 Feb;41(2):119-20 [8656411.001]
  • [Cites] AJR Am J Roentgenol. 1996 Aug;167(2):475-6 [8686629.001]
  • [Cites] Am J Pathol. 1997 Jun;150(6):2153-66 [9176406.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 1996 Oct;25(5):270-2 [9388869.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1998 Feb;76(2):189-91 [9481573.001]
  • [Cites] Int J Gynaecol Obstet. 1998 May;61(2):191-2 [9639228.001]
  • [Cites] J Ultrasound Med. 1998 Nov;17(11):699-703 [9805306.001]
  • [Cites] Nat Genet. 1998 Dec;20(4):358-61 [9843207.001]
  • [Cites] Abdom Imaging. 1998 Nov-Dec;23(6):640-4 [9922202.001]
  • [Cites] Gynecol Oncol. 1999 Oct;75(1):158-63 [10502446.001]
  • [Cites] Gynecol Oncol. 2004 Dec;95(3):742-5 [15581996.001]
  • [Cites] BMC Gastroenterol. 2005;5:33 [16223449.001]
  • [Cites] Birth Defects Res A Clin Mol Teratol. 2006 Mar;76(3):205-9 [16498628.001]
  • [Cites] AJR Am J Roentgenol. 1981 Aug;137(2):395-8 [6789651.001]
  • [Cites] Neurologia. 1999 Nov;14(9):460-2 [10613021.001]
  • [Cites] Am J Hum Genet. 2000 Jan;66(1):312-9 [10631160.001]
  • [Cites] Br J Surg. 1973 Apr;60(4):271-4 [4700226.001]
  • [Cites] Am J Obstet Gynecol. 2000 Mar;182(3):725-6 [10739537.001]
  • (PMID = 16686944.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Receptors, Steroid
  • [Other-IDs] NLM/ PMC1481579
  •  go-up   go-down






Advertisement